Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market Revenue to Attain USD 32.05 Bn by 2033

13 Jun 2025

Share :

Table of Content

1. Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market Revenue and Trends 2025 to 2033 2. Market Overview: Exploring the Growth Potential 3. Segment Insights 4. Regional Insights 5. Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market Coverage 6. Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market Key Players

Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market Revenue and Trends 2025 to 2033

The global non-alcoholic fatty liver disease (NAFLD) drug market revenue reached USD 21.98 billion in 2025 and is predicted to attain around USD 32.05 billion by 2033 with a CAGR of 4.83%. The growth of the market is attributed to the rising research and development to identify new drug targets and the increasing burden of liver diseases worldwide.

Market Overview: Exploring the Growth Potential

The global non-alcoholic fatty liver disease (NAFLD) drug market is experiencing significant growth, driven by a rise in sedentary lifestyles and unhealthy eating habits, which lead to increased rates of obesity and type 2 diabetes. These conditions are directly linked to NAFLD, a most common chronic liver disorders in the world, especially in developed countries. As the burden of NAFLD increases, so does the need for pharmacological treatments.

Healthcare providers and patients are increasingly becoming aware of the long-term complications of untreated NAFLD. If NAFLD remains untreated, it can lead to cirrhosis, liver cancer, and cardiovascular disease. Rising investments in research and development, increasing number of clinical trials in fatty liver disease, specifically targeting NASH (non-alcoholic steatohepatitis) - a more severe manifestation of NAFLD, and the increasing therapeutic pipeline for NAFLD are some of the major factors driving the growth of the market.

Segment Insights

• By drug class, the antioxidants segment held the largest revenue share of the market in 2024. This is mainly due to their proven effectiveness in treating liver disease, inhibiting the development of hepatic dysfunction. They have been used in the treatment of NAFLD due to their critical role in mitigating oxidative stress, which leads to rapid NAFLD development.
• By stage, the cirrhosis segment led the market with a major revenue share in 2024. Cirrhosis is considered an early stage of NAFLD. There is a high demand for effective therapeutics due to the severe nature of cirrhosis and the associate mortality rate.
• By distribution channel, the hospital pharmacies segment accounted for the largest share in 2024. Since hospitals considered as primary healthcare center, there is a significant rise in patient pool, boosting the demand for NAFLD drugs.
• By disease cause, the obesity segment dominated the market in 2024, as it is a significant risk factor in the initiation and progression of NAFLD.

Regional Insights

In 2024, North America dominated the global market by holding the largest share. This is mainly due to its advanced healthcare system, high prevalence of diabetes and obesity, and increased investment in R&D and drug discovery and development. Meanwhile, Asia Pacific is emerging as a rapidly growing area. This is mainly due to the rising prevalence of type 2 diabetes and liver diseases, increased healthcare expenditure, and rising number of clinical trials.

Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market Coverage

Recent Development

• In March 2024, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise.
  (Source: https://www.fda.gov)

Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market Key Players

• Pfizer Inc.
• Takeda
• Intercept Pharmaceuticals
• Roche
• AstraZeneca
• Novartis AG
• Merck & Co.
• Inc.
• AbbVie Inc.
• Gilead Sciences, Inc.

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6215

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com|+1 804 441 9344